newsfilter
← Earnings
Earnings Releases·

SINTX Technologies — Third Quarter 2026 Earnings Summary

SINTX Technologies reported a tenfold increase in third-quarter 2026 revenue to approximately $2.2 million, driven by the commercial launch of its FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System. The company achieved a gross margin of 62% and reduced its operating loss by 51% to $1.6 million compared to the prior-year period. Additionally, SINTX regained compliance with Nasdaq's minimum stockholders' equity requirement and secured $2.0 million in proceeds from warrant exercises following the quarter's revenue milestone.

Company
SINTX TECHNOLOGIES INC
Sector
Healthcare
Industry
Medical Devices